Servier disburses €114 Million for Taiho’s Colorectal Cancer treatment

19/06/2015 - 2 minutes

Servier is fattening up its oncology assests with the acquisition of Taiho Pharmaceutical’s treatment of refractory mestatic colorectal cancer. The French laboratories will commercialize the molecule in Europe and other countries.

Taiho Pharmaceutical and Servier come to an agreement for the development and commercialization of TAS-102 in Europe. The drug is an oral combination anticancer drug initially developed by Taiho Pharmaceutical for use in the treatment of refractory metastatic colorectal cancer.

The treatment was approved in Japan in 2014 and is currently being reviewed by Health Authorities in Europe and the United States. It consists of the combination of an antitumor agent, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. The antitumor agent induces DNA dysfunction through incorporation into DNA, which inhibits tumor growth. Alternatively, the phosphorylase inhibitor prevents degradation of the first compound, thereby allowing a more sustained inhibitory effect.

Under this agreement, Taiho Pharmaceutical will receive a total of €113,9M in an upfront payment. In addition, Taiho will receive further regulatory and sales event milestone payments and royalties based on net sales.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member